Roger S McIntyre

Summary

Affiliation: University of Toronto
Country: Canada

Publications

  1. ncbi request reprint Valproate, bipolar disorder and polycystic ovarian syndrome
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada
    Bipolar Disord 5:28-35. 2003
  2. ncbi request reprint The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, Departments of Psychiatry and Pharmacology, University of Toronto, Toronto, Ontario, Canada
    Ann Clin Psychiatry 24:69-81. 2012
  3. doi request reprint A review of FDA-approved treatment options in bipolar depression
    Roger S McIntyre
    1 Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    CNS Spectr 18:4-20; quiz 21. 2013
  4. ncbi request reprint Substance use disorders and overweight/obesity in bipolar I disorder: preliminary evidence for competing addictions
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Ontario, Canada
    J Clin Psychiatry 68:1352-7. 2007
  5. ncbi request reprint Should Depressive Syndromes Be Reclassified as "Metabolic Syndrome Type II"?
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, ON, Canada
    Ann Clin Psychiatry 19:257-64. 2007
  6. ncbi request reprint A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states
    Roger S McIntyre
    Department of Psychiatry and Pharmacology, University of Toronto, Toronto, ON, Canada
    Bipolar Disord 11:673-86. 2009
  7. doi request reprint A randomized, double-blind, controlled trial evaluating the effect of intranasal insulin on neurocognitive function in euthymic patients with bipolar disorder
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    Bipolar Disord 14:697-706. 2012
  8. ncbi request reprint Frequency and correlates of gambling problems in outpatients with major depressive disorder and bipolar disorder
    Sidney H Kennedy
    University of Toronto, Ontario, Canada
    Can J Psychiatry 55:568-76. 2010
  9. ncbi request reprint Quetiapine in the treatment of acute bipolar mania: efficacy across a broad range of symptoms
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada
    J Affect Disord 100:S5-14. 2007
  10. ncbi request reprint Medical comorbidity in bipolar disorder: re-prioritizing unmet needs
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    Curr Opin Psychiatry 20:406-16. 2007

Collaborators

Detail Information

Publications113 found, 100 shown here

  1. ncbi request reprint Valproate, bipolar disorder and polycystic ovarian syndrome
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada
    Bipolar Disord 5:28-35. 2003
    ..Recent data suggest that valproic acid, a commonly prescribed mood stabilizer, may be associated with polycystic ovarian syndrome (PCOS). This adverse event has not been systematically studied in bipolar disorder...
  2. ncbi request reprint The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, Departments of Psychiatry and Pharmacology, University of Toronto, Toronto, Ontario, Canada
    Ann Clin Psychiatry 24:69-81. 2012
    ..Our group conducted a comprehensive literature review to provide evidence-based recommendations for treating metabolic comorbidity in individuals with major depressive disorder (MDD) and bipolar disorder (BD)...
  3. doi request reprint A review of FDA-approved treatment options in bipolar depression
    Roger S McIntyre
    1 Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    CNS Spectr 18:4-20; quiz 21. 2013
    ..OBJECTIVES/INTRODUCTION: Herein we review the evidence supporting Food and Drug Administration (FDA) approved and emerging treatments for bipolar depression...
  4. ncbi request reprint Substance use disorders and overweight/obesity in bipolar I disorder: preliminary evidence for competing addictions
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Ontario, Canada
    J Clin Psychiatry 68:1352-7. 2007
    ..This investigation was undertaken to explore the relationship between alcohol/illicit drug dependence and overweight/obesity in individuals with bipolar I disorder...
  5. ncbi request reprint Should Depressive Syndromes Be Reclassified as "Metabolic Syndrome Type II"?
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, ON, Canada
    Ann Clin Psychiatry 19:257-64. 2007
    ..A nascent explanatory theory regarding the pathophysiology of major depressive disorder posits that alterations in metabolic networks (e.g., insulin and glucocorticoid signaling) mediate allostasis...
  6. ncbi request reprint A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states
    Roger S McIntyre
    Department of Psychiatry and Pharmacology, University of Toronto, Toronto, ON, Canada
    Bipolar Disord 11:673-86. 2009
    ..Asenapine is approved for bipolar disorder and schizophrenia. This was a 3-week, randomized, double-blind, placebo-controlled trial of asenapine for treating acute bipolar mania...
  7. doi request reprint A randomized, double-blind, controlled trial evaluating the effect of intranasal insulin on neurocognitive function in euthymic patients with bipolar disorder
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    Bipolar Disord 14:697-706. 2012
    ..In keeping with this view, we tested the hypothesis that intranasal insulin administration would improve measures of neurocognitive performance in euthymic adults with bipolar disorder...
  8. ncbi request reprint Frequency and correlates of gambling problems in outpatients with major depressive disorder and bipolar disorder
    Sidney H Kennedy
    University of Toronto, Ontario, Canada
    Can J Psychiatry 55:568-76. 2010
    ....
  9. ncbi request reprint Quetiapine in the treatment of acute bipolar mania: efficacy across a broad range of symptoms
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada
    J Affect Disord 100:S5-14. 2007
    ..This post-hoc analysis aims to extend our understanding of quetiapine's antimanic efficacy by evaluating its therapeutic effect across the full spectrum of manic symptoms...
  10. ncbi request reprint Medical comorbidity in bipolar disorder: re-prioritizing unmet needs
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    Curr Opin Psychiatry 20:406-16. 2007
    ..The aim of this review is to synthesize results from extant investigations which report on the co-occurrence of bipolar disorder and medical comorbidity...
  11. ncbi request reprint Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Ontario, Canada
    Psychiatr Serv 57:1140-4. 2006
    ..This is the first cross-national population-based investigation exploring the prevalence and functional implications of comorbid general medical disorders in bipolar disorder...
  12. ncbi request reprint Thiazolidinediones: novel treatments for cognitive deficits in mood disorders?
    Roger S McIntyre
    University of Toronto, Department of Psychiatry, Toronto, ON, Canada
    Expert Opin Pharmacother 8:1615-28. 2007
    ..Extant data provide the basis for formulating a hypothesis that TZDs may be salutary for cognitive deficits and several aspects of somatic health (e.g., cardiovascular disease) associated with mood disorders...
  13. ncbi request reprint Metabolic syndrome and major depressive disorder: co-occurrence and pathophysiologic overlap
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, 399 Bathurst Street, Toronto, Ontario M5T 2S8, Canada
    Curr Diab Rep 9:51-9. 2009
    ..This article discusses the rate of co-occurrence and the points of pathophysiologic commonality between the metabolic syndrome and major depressive disorder...
  14. doi request reprint Aerobic physical exercise as a possible treatment for neurocognitive dysfunction in bipolar disorder
    Aaron Kucyi
    Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada
    Postgrad Med 122:107-16. 2010
    ..The overarching aim of this review is to emphasize that aerobic physical exercise is a viable neurocognitive-enhancing adjunctive treatment for patients with BD...
  15. ncbi request reprint Problem gambling in bipolar disorder: results from the Canadian Community Health Survey
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    J Affect Disord 102:27-34. 2007
    ..This investigation was undertaken to explore the prevalence and associated features of problem gambling amongst individuals with bipolar I disorder...
  16. ncbi request reprint Acetyl-L-carnitine and alpha-lipoic acid: possible neurotherapeutic agents for mood disorders?
    Joanna K Soczynska
    University of Toronto, Institute of Medical Science, Toronto, ON, Canada
    Expert Opin Investig Drugs 17:827-43. 2008
    ..Mood disorders are associated with decrements in cognitive function, which are insufficiently treated with contemporary pharmacotherapies...
  17. doi request reprint Bipolar disorder and metabolic syndrome: an international perspective
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    J Affect Disord 126:366-87. 2010
    ....
  18. doi request reprint Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, ON, Canada
    J Affect Disord 126:358-65. 2010
    ..We report the results of long-term treatment with asenapine in patients with bipolar I disorder...
  19. ncbi request reprint Bipolar disorder and suicide: research synthesis and clinical translation
    Roger S McIntyre
    Department of Psychiatry and Pharmacology, University of Toronto, Mood Disorders Psychopharmacology Unit, University Health Network, 399 Bathurst Street, Toronto, Ontario M5T 2S8, Canada
    Curr Psychiatry Rep 10:66-72. 2008
    ..A nascent database suggests that adjunctive psychosocial interventions may further reduce suicide risk in bipolar individuals...
  20. doi request reprint The effect of personality dimensions on functional outcomes in mood disorders
    Jessica Leen
    Mood Disorders Psychopharmacology Unit, University Health Network, 399 Bathurst Street, Toronto, ON M5T 2S8, Canada
    Adv Ther 30:671-83. 2013
    ..Functional impairment associated with mood disorders may be related to a characteristic "profile" of normative personality dimensions...
  21. doi request reprint Obesity and mental illness: implications for cognitive functioning
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    Adv Ther 30:577-88. 2013
    ..Research endeavors that aim to refine mediators and moderators of this association as well as novel strategies to reverse the injurious process of obesity on cognition are warranted. ..
  22. doi request reprint The effect of lisdexamfetamine dimesylate on body weight, metabolic parameters, and attention deficit hyperactivity disorder symptomatology in adults with bipolar I/II disorder
    Roger S McIntyre
    Institute of Medical Science, University of Toronto, Toronto, Canada Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Canada Department of Psychiatry, University of Toronto, Toronto, Canada Department of Pharmacology, University of Toronto, Toronto, Canada Department of Psychiatry, University Health Network, Toronto, Canada
    Hum Psychopharmacol 28:421-7. 2013
    ..Our secondary aim was to evaluate the effect of LDX on attention deficit hyperactivity disorder (ADHD) symptom severity in adults with bipolar I/II disorder...
  23. doi request reprint Novel therapeutic targets in depression: minocycline as a candidate treatment
    Joanna K Soczynska
    Institute of Medical Science, University of Toronto, Toronto, Canada
    Behav Brain Res 235:302-17. 2012
    ..Herein, we provide the rationale for conducting a randomized, controlled trial to test the antidepressant properties of minocycline...
  24. doi request reprint When should you move beyond first-line therapy for depression?
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    J Clin Psychiatry 71:16-20. 2010
    ..Taken together, practitioners are often faced with the critical question as to when to move beyond index therapy for treating depressive symptoms as part of MDD...
  25. doi request reprint Asenapine versus olanzapine in acute mania: a double-blind extension study
    Roger S McIntyre
    Department of Psychiatry and Pharmacology, University of Toronto, Toronto, ON, Canada
    Bipolar Disord 11:815-26. 2009
    ..To assess the efficacy and tolerability of asenapine versus olanzapine in the extended treatment of bipolar mania...
  26. ncbi request reprint Residual anxiety symptoms in depressed primary care patients
    Roger S McIntyre
    University of Toronto, Toronto, Ontario, Canada
    J Psychiatr Pract 13:125-8. 2007
    ..The goal of this study was to characterize the burden of anxiety among residual depressive symptoms in naturalistic primary care settings...
  27. ncbi request reprint Comparing features of bipolar disorder to major depressive disorder in a tertiary mood disorders clinic
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, ON, Canada
    Ann Clin Psychiatry 19:313-7. 2007
    ..We sought to describe features that distinguish individuals with bipolar disorder from major depressive disorder...
  28. ncbi request reprint Overview of managing medical comorbidities in patients with severe mental illness
    Roger S McIntyre
    Department of Psychiatry and Pharmacology, University of Toronto, and the Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada
    J Clin Psychiatry 70:e17. 2009
    ..Coordinated somatic and psychiatric treatment, weight-neutral or weight-reducing pharmaceuticals, and behavioral weight management programs may help lessen the burden of CVD in the mental health population...
  29. ncbi request reprint Antipsychotic-induced weight gain: bipolar disorder and leptin
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    J Clin Psychopharmacol 23:323-7. 2003
    ..05). The temporal association between weight increase and leptin changes does not support the notion that leptin is a primary promoter of antipsychotic-induced weight gain; however, a secondary perpetuating role cannot be ruled out...
  30. ncbi request reprint Relationship between regional brain metabolism, illness severity and age in depressed subjects
    Jakub Z Konarski
    Institute of Medical Science, University of Toronto, Toronto, ON, Canada
    Psychiatry Res 155:203-10. 2007
    ..The age-dependent changes documented herein may influence the distinct clinical presentation and treatment response described in older-age depression...
  31. doi request reprint A review of published evidence reporting on the efficacy and pharmacology of lurasidone
    Roger S McIntyre
    University Health Network, Mood Disorders Psychopharmacology Unit, 399 Bathurst Street, Toronto, Ontario, M5T 2S8, Canada
    Expert Opin Pharmacother 13:1653-9. 2012
    ..Lurasidone is not known to adversely affect body composition, anthropometrics, metabolic and/or electrocardiographic parameters. Although prolactin elevation might be observed, prolactin-related adverse events are rarely reported...
  32. ncbi request reprint The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid personality disorders
    Michael Rosenbluth
    Toronto East General Hospital Day, Treatment Program, East York, Ontario, Canada
    Ann Clin Psychiatry 24:56-68. 2012
    ..There is a need for recommendations to assist clinicians in treating these frequently encountered patients...
  33. doi request reprint Mood disorders and obesity: understanding inflammation as a pathophysiological nexus
    Joanna K Soczynska
    Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada
    Neuromolecular Med 13:93-116. 2011
    ..This clinical recommendation is amplified in individuals presenting with biochemical indicators of insulin resistance and other concurrent conditions associated with abnormal inflammatory signaling (e.g. cardiovascular disease)...
  34. ncbi request reprint The relationship between testosterone and sexual function in depressed and healthy men
    Sakina J Rizvi
    University Health Network, Department of Psychiatry, Toronto, Canada
    J Sex Med 7:816-25. 2010
    ..The objective of this study is to evaluate the effects of depression and low testosterone across various domains of sexual function...
  35. ncbi request reprint Maintenance treatment in bipolar disorder: a focus on aripiprazole
    Roger S McIntyre
    University of Toronto, Department of Psychiatry, Department of Pharmacology, Toronto, ON, Canada
    Expert Rev Neurother 7:919-25. 2007
    ..This article provides a succinct review of treatments approved by the US FDA for maintenance in bipolar disorders, with a focus on the most recently approved atypical antipsychotic, aripiprazole...
  36. ncbi request reprint Polypharmacy in children and adolescents treated for major depressive disorder: a claims database study
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    J Clin Psychiatry 70:240-6. 2009
    ..To describe the rate and trajectory of change in psychiatric polypharmacy during the past decade in children and adolescents treated for major depressive disorder...
  37. ncbi request reprint Improving outcomes in depression: a focus on somatic symptoms
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    J Psychosom Res 60:279-82. 2006
    ..It is hypothesized that somatic symptom alleviation is a significant predictor of overall outcome in depressed primary care patients...
  38. doi request reprint Brain volume abnormalities and neurocognitive deficits in diabetes mellitus: points of pathophysiological commonality with mood disorders?
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, 399 Bathurst Street, Toronto, Ontario, Canada
    Adv Ther 27:63-80. 2010
    ..It is hypothesized that diabetes mellitus (DM) and mood disorders share points of pathophysiological commonality in the central nervous system...
  39. ncbi request reprint Anxiety disorders and bipolar disorder: a review
    Roger S McIntyre
    Department of Psychiatry and Pharmacology, University Health Network, University of Toronto, 399 Bathurst Street, Toronto, Ontario, Canada
    Bipolar Disord 8:665-76. 2006
    ..Anxiety comorbidity in the BPD population poses a serious hazard. For example, it is associated with an intensification of symptoms, non-recovery, substance use comorbidity and harmful dysfunction (e.g., suicidality)...
  40. doi request reprint Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents
    Roger S McIntyre
    Department of Psychiatry and Pharmacology, Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada
    Arch Pediatr Adolesc Med 162:929-35. 2008
    ..To identify factors associated with incident cardiovascular events and metabolic disturbance in children and adolescents treated with antipsychotics...
  41. ncbi request reprint Understanding needs, interactions, treatment, and expectations among individuals affected by bipolar disorder or schizophrenia: the UNITE global survey
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, 399 Bathurst St, Toronto, Ontario, Canada M5T 2S8, Canada
    J Clin Psychiatry 70:5-11. 2009
    ....
  42. ncbi request reprint The effect of antidepressants on lipid homeostasis: a cardiac safety concern?
    Roger S McIntyre
    University of Toronto, Department of Psychiatry, Toronto, ON, Canada
    Expert Opin Drug Saf 5:523-37. 2006
    ..The authors sought to summarise and synthesise results from investigations which report on the effect of antidepressants on serum lipid homeostasis...
  43. doi request reprint The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    CNS Drugs 24:741-53. 2010
    ..Initiating and maintaining antidepressant therapy should include routine surveillance for clinical and/or biochemical evidence suggestive of the metabolic syndrome...
  44. ncbi request reprint Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Mood and Anxiety Disorders Program, Center for Addiction and Mental Health, Clarke Site, Ontario, Canada
    Bipolar Disord 4:207-13. 2002
    ....
  45. ncbi request reprint Neural response to emotional stimuli associated with successful antidepressant treatment and behavioral activation
    Sakina J Rizvi
    Departments of Pharmaceutical Sciences and Neuroscience, University of Toronto, Toronto, Ontario, Canada Department of Psychiatry, University Health Network, Toronto, Ontario, Canada Electronic address
    J Affect Disord 151:573-81. 2013
    ..Several lines of research have demonstrated that MDD patients experience impairments in various components of affective processing, including regulation of affective states...
  46. doi request reprint The neuroprotective effects of GLP-1: possible treatments for cognitive deficits in individuals with mood disorders
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    Behav Brain Res 237:164-71. 2013
    ..Systematic evaluation of the effects of GLP-1 treatment in psychiatric populations who evince cognitive deficits represents a promising treatment avenue...
  47. ncbi request reprint The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders
    Ayal Schaffer
    Mood and Anxiety Disorders Program, Sunnybrook Health Sciences Centre, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    Ann Clin Psychiatry 24:6-22. 2012
    ..This article is part of a set of Canadian Network for Mood and Anxiety Treatments (CANMAT) Comorbidity Task Force papers...
  48. ncbi request reprint The relationship between childhood abuse and suicidality in adult bipolar disorder
    Roger S McIntyre
    Department of Psychiatry and Pharmacology, University of Toronto, University Health Network, Toronto, Ontario, Canada
    Violence Vict 23:361-72. 2008
    ..Anamnestic inquiry regarding childhood maltreatment is salient to risk assessment, illness management planning, preventative strategies, and treatment interventions in bipolar disorder...
  49. ncbi request reprint Acute treatment of patients with bipolar mixed episodes
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, and the Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada
    J Clin Psychiatry 69:e10. 2008
    ..As more medications become available in the treatment of bipolar disorder, algorithms can help clinicians make the appropriate treatment choices by offering recommendations for sequencing agents...
  50. ncbi request reprint Aripiprazole: pharmacology and evidence in bipolar disorder
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    Expert Opin Pharmacother 8:1001-9. 2007
    ..Aripiprazole constitutes an alternative mood-stabilizing pharmacologic avenue in bipolar disorder; its comparative efficacy in long-term recurrence prevention and bipolar depression is a future research vista...
  51. ncbi request reprint Insulin, insulin-like growth factors and incretins: neural homeostatic regulators and treatment opportunities
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    CNS Drugs 22:443-53. 2008
    ..The neuroactive peptides, insulin, IGF-1 and incretins, or agents that facilitate their central effects (e.g. insulin-sensitizing agents), may constitute novel and possibly disease-modifying neurocognitive treatments...
  52. ncbi request reprint The hepatic safety profile of duloxetine: a review
    Roger S McIntyre
    University Health Network, Mood Disorders Psychopharmacology Unit, 399 Bathurst Street, Toronto, ON, M5T 2S8, Canada
    Expert Opin Drug Metab Toxicol 4:281-5. 2008
    ..Hepatotoxicity related to the use of duloxetine resulted in rewording of the US product insert...
  53. ncbi request reprint The prevalence and impact of migraine headache in bipolar disorder: results from the Canadian Community Health Survey
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Mood Disorders Psychopharmacology Unit, University Health Network, 399 Bathurst Street, Toronto, ON, Canada M5T 2S8
    Headache 46:973-82. 2006
    ..To report on the prevalence of comorbid migraine in bipolar disorder and the implications for bipolar age of onset, psychiatric comorbidity, illness course, functional outcome, and medical service utilization...
  54. doi request reprint Relation between cigarette smoking and cognitive function in euthymic individuals with bipolar disorder
    Candy W Y Law
    Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada
    Pharmacol Biochem Behav 92:12-6. 2009
    ..Emerging evidence indicates that both smoking and cognitive deficits are associated with more severe illness presentation and course...
  55. ncbi request reprint Psychotropic drugs and adverse events in the treatment of bipolar disorders revisited
    Roger S McIntyre
    Mood Disorders Program, Centre for Addiction and Mental Health, Clarke Division, University of Toronto, Ontario, Canada
    J Clin Psychiatry 63:15-20. 2002
    ..Most of their adverse effects can be avoided by slow titration toward the recommended doses. In contrast to carbamazepine and valproic acid, topiramate may be associated with weight loss...
  56. doi request reprint Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions
    Roger S McIntyre
    Institute of Medical Science, University of Toronto, Toronto, Canada
    Depress Anxiety 30:515-27. 2013
    ..Few reports have aimed to describe the mediational effect of cognitive deficits on functional outcomes in major depressive disorder (MDD), and relatively few interventions are demonstrated to mitigate cognitive deficits in MDD...
  57. ncbi request reprint Beyond pharmacotherapy: understanding the links between obesity and chronic mental illness
    Valerie H Taylor
    Women s College Hospital, Toronto, Ontario
    Can J Psychiatry 57:5-12. 2012
    ..Our review examines issues associated with common chronic mental illnesses that may underlie this association and warrant further study if we hope to clinically intervene to control this life-threatening comorbidity...
  58. ncbi request reprint Managing medical and psychiatric comorbidity in individuals with major depressive disorder and bipolar disorder
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    Ann Clin Psychiatry 24:163-9. 2012
    ..Treating comorbid conditions in patients with mood disorders requires sufficient decision support to inform appropriate treatment...
  59. doi request reprint Efficacy of antimanic treatments in mixed states
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    Bipolar Disord 14:22-36. 2012
    ..To review the efficacy of pharmacological agents in bipolar mixed states...
  60. ncbi request reprint Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, Ontario M5T 1R8, Canada
    J Clin Psychiatry 66:28-36. 2005
    ..This article reviews relevant adverse events attributable to the use of atypical antipsychotic agents, with particular consideration of the bipolar disorder population...
  61. ncbi request reprint Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada
    Ann Clin Psychiatry 17:83-93. 2005
    ..Preliminary investigations indicate that patients who suffer from BD with comorbid DM have a more severe course and outcome, lower quality of life, higher prevalence of medical comorbidity and higher cost of illness...
  62. ncbi request reprint Neuroimaging approaches in mood disorders: technique and clinical implications
    Jakub Z Konarski
    Mood Disorders Psychopharmacology Unit, University Health Network, ON, Canada
    Ann Clin Psychiatry 19:265-77. 2007
    ..The encompassing aim of this review is to provide the mental health care practitioner with a pragmatic understanding of neuroimaging approaches and their possible clinical application...
  63. doi request reprint Volumetric neuroimaging investigations in mood disorders: bipolar disorder versus major depressive disorder
    Jakub Z Konarski
    Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada
    Bipolar Disord 10:1-37. 2008
    ..Patient and methodological variability complicates the comparison of neuroimaging study results and limits heuristic model development and a biologically-based diagnostic schema...
  64. ncbi request reprint Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial
    Sidney H Kennedy
    University Health Network, Institute of Medical Science, University of Toronto, Department of Psychiatry, and Toronto General Hospital, 200 Elizabeth St, Eaton North Wing 8 222, Toronto, Ontario M5G 2C4, Canada
    Am J Psychiatry 164:778-88. 2007
    ..In this study, the authors report changes in fluorine-18-fluorodeoxyglucose PET in responders to CBT or venlafaxine during a randomized controlled trial...
  65. ncbi request reprint Managing weight gain in patients with severe mental illness
    Roger S McIntyre
    Department of Psychiatry and Pharmacology, University of Toronto, and the Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada
    J Clin Psychiatry 70:e23. 2009
    ....
  66. doi request reprint Long-term treatment of bipolar disorder in adults
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Ontario, Canada
    J Clin Psychiatry 72:e06. 2011
    ..Additionally, psychotherapies are effective when used in combination with pharmacotherapy...
  67. doi request reprint Neurosurgical treatment of bipolar depression: defining treatment resistance and identifying surgical targets
    Nir Lipsman
    Division of Neurosurgery, University Health Network Department of Psychiatry, University of Toronto, University Health Network, 399 Bathurst Street, Toronto, Ontario, Canada
    Bipolar Disord 12:691-701. 2010
    ..Herein, we provide the rationale for employing DBS as an alternative treatment avenue in individuals with bipolar depression...
  68. pmc Hormone replacement therapy and antidepressant prescription patterns: a reciprocal relationship
    Roger S McIntyre
    University Health Network, and Department of Psychiatry, University of Toronto, Toronto, Ont
    CMAJ 172:57-9. 2005
  69. ncbi request reprint A preclinical and clinical rationale for quetiapine in mood syndromes
    Roger S McIntyre
    University of Toronto, Department of Psychiatry, Toronto, ON, Canada
    Expert Opin Pharmacother 8:1211-9. 2007
    ..The in vitro pharmacodynamic profile of quetiapine is predictive of antidepressant activity in mood syndromes. Available clinical evidence has established quetiapine as an effective monotherapy in bipolar depression...
  70. ncbi request reprint Managing psychiatric disorders with antidiabetic agents: translational research and treatment opportunities
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, 399 Bathurst Street Toronto, ON, M5T 2S8, Canada
    Expert Opin Pharmacother 7:1305-21. 2006
    ..Antidiabetic treatments, which maintain euglycaemia, hold promise as potent and clinically significant therapeutic interventions for several neuropsychiatric disorders...
  71. ncbi request reprint The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms
    Roger S McIntyre
    University of Toronto, Department of Psychiatry, University Health Network, 399 Bathurst Street, Toronto, ON, M5T 2S8, Canada
    Expert Opin Drug Saf 5:157-68. 2006
    ..To synthesise results from investigations reporting on the effect of antidepressants on glucose-insulin homeostasis...
  72. doi request reprint Asenapine: a review of acute and extension phase data in bipolar disorder
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    CNS Neurosci Ther 17:645-8. 2011
    ..Bipolar depression and recurrence prevention studies are required to fully characterize this novel agent's position in the treatment of bipolar disorder...
  73. doi request reprint Asenapine: a synthesis of efficacy data in bipolar mania and schizophrenia
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, Canada
    Clin Schizophr Relat Psychoses 5:217-20. 2012
    ..This article briefly reviews the efficacy, as well as safety and tolerability, data pertaining to asenapine in bipolar mania and schizophrenia. Postulated mechanism of action is also reviewed...
  74. doi request reprint Exercise and bipolar disorder: a review of neurobiological mediators
    Mohammad T Alsuwaidan
    Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    Neuromolecular Med 11:328-36. 2009
    ..g., public health dose), a testable hypothesis is that structured exercise is capable of improving psychiatric and somatic health in BD...
  75. ncbi request reprint Calculated bioavailable testosterone levels and depression in middle-aged men
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    Psychoneuroendocrinology 31:1029-35. 2006
    ..We sought to determine the relationship between physiologically active bioavailable testosterone (BT) and depressive symptoms in middle-aged men with and without major depressive disorder (MDD)...
  76. ncbi request reprint Thiazolidinediones: from antioxidant to neurotherapeutic?
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, Ont, Canada
    Med Hypotheses 69:773-7. 2007
    ..We propose that TZDs constitute a potentially novel disease-modifying treatment avenue for mood disorders...
  77. ncbi request reprint Open-label adjunctive topiramate in the treatment of unstable bipolar disorder
    Roger S McIntyre
    Mood Disorders Psychoparmacology Unit, University Health Network, Toronto, Ontario
    Can J Psychiatry 50:415-22. 2005
    ..To assess open-label adjunctive topiramate in the treatment of outpatients with unstable bipolar disorder (BD)...
  78. doi request reprint Teratogenesis associated with antibipolar agents
    Ha T T Nguyen
    Department of Psychiatry, Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada
    Adv Ther 26:281-94. 2009
    ..To review the teratogenic effects associated with the use of Food and Drug Administration-approved agents for bipolar disorder...
  79. ncbi request reprint Bipolar disorder: a national health concern
    Roger S McIntyre
    University Health Network, Edith Cavell Wing 3D 003, 399 Bathurst St, M5T 2S8, Ontario, Canada
    CNS Spectr 9:6-15. 2004
    ....
  80. ncbi request reprint Quetiapine or haloperidol as monotherapy for bipolar mania--a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Canada
    Eur Neuropsychopharmacol 15:573-85. 2005
    ..The primary efficacy outcome variable was change from baseline to Day 21 in Young Mania Rating Scale (YMRS) score...
  81. ncbi request reprint Risk of weight gain associated with antipsychotic treatment: results from the Canadian National Outcomes Measurement Study in Schizophrenia
    Roger S McIntyre
    Mood Disorders Psychopharmacology Clinic, Department of Psychiatry, University of Toronto, University Health Network, Toronto Western Hospital, 399 Bathurst Street, Toronto, ON M5T2S8
    Can J Psychiatry 48:689-94. 2003
    ..This investigation describes comparative NAP-induced weight gain in a prospective naturalistic cohort of persons with schizophrenia and related psychotic disorders...
  82. ncbi request reprint Duloxetine: pharmacoeconomic implications of an antidepressant that alleviates painful physical symptoms
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    Expert Opin Pharmacother 6:707-13. 2005
    ..Pharmacoeconomic and cost-impact modelling analyses should be reformulated to consider duloxetine's symptom-alleviating effect on the somatic dimension of depressive illness...
  83. ncbi request reprint The human cost of not achieving full remission in depression
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Ontario
    Can J Psychiatry 49:10S-16S. 2004
    ....
  84. ncbi request reprint Comorbidity in bipolar disorder: a framework for rational treatment selection
    Roger S McIntyre
    Mood Disorder Psychopharmacology Unit, University of Toronto, University Health Network Toronto Western Hospital, 399 Bathurst Street, Toronto, Ontario M5T 2S9, Canada
    Hum Psychopharmacol 19:369-86. 2004
    ..This schema should be further informed by the treatment data for comorbid and accessory conditions. The authors propose a schema to provide the impetus for further work in the area...
  85. pmc Treating bipolar disorder. Evidence-based guidelines for family medicine
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Ont
    Can Fam Physician 50:388-94. 2004
    ..To provide an evidence-based summary of medications commonly used for bipolar disorders and a practical approach to managing bipolar disorders in the office...
  86. ncbi request reprint The antidepressant effects of risperidone and olanzapine in bipolar disorder
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Ontario
    Can J Clin Pharmacol 11:e218-26. 2004
    ..To describe the antidepressant effectiveness of olanzapine and risperidone and compare their tolerability when employed adjunctively in bipolar I/II disorder...
  87. pmc What to do if an initial antidepressant fails?
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Ont
    Can Fam Physician 49:449-57. 2003
    ..To provide family physicians with practical ways of managing depressed patients responding insufficiently to initial antidepressant treatment...
  88. ncbi request reprint Predictors of self-reported antidepressant adherence
    Tara A Burra
    Faculty of Medicine, University of Toronto, Ontario, Canada
    Behav Med 32:127-34. 2007
    ..Clinicians should be cognizant of this complexity and address not only issues related to medication efficacy and tolerability, but also social mediators and health beliefs when prescribing antidepressants...
  89. ncbi request reprint Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a cost-effectiveness analysis
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, Ontario, Canada
    J Eval Clin Pract 16:744-55. 2010
    ....
  90. pmc Reboxetine: a preliminary report on its use through the Special Access Program
    Sidney H Kennedy
    University Health Network, Department of Psychiatry, University of Toronto, Toronto, Ont
    J Psychiatry Neurosci 27:418-22. 2002
    ..To describe the effectiveness and tolerability of reboxetine under Special Access Program conditions in Canada in a group of patients with refractory depressive disorders...
  91. doi request reprint Pharmacology and efficacy of asenapine for manic and mixed states in adults with bipolar disorder
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    Expert Rev Neurother 10:645-9. 2010
    ..Its antidepressant and recurrence prevention effects in bipolar disorder are under investigation, as is its possible role in major depressive disorder...
  92. ncbi request reprint Measurable outcomes in psychiatric disorders: remission as a marker of wellness
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, Ontario, Canada
    Clin Ther 28:1882-91. 2006
    ..Collectively, they are associated with significant morbidity, mortality, and economic cost. Wellness is the optimal outcome in the management of chronic medical and psychiatric disorders...
  93. ncbi request reprint Sex differences in antidepressant response in a Canadian primary-care sample
    Sophie Grigoriadis
    J Clin Psychopharmacol 27:95-8. 2007
  94. pmc An approach to managing depression. Defining and measuring outcomes
    Atul Khullar
    Department of Psychiatry, University of Alberta, Edmonton
    Can Fam Physician 50:1374-80. 2004
    ....
  95. ncbi request reprint Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges
    W Wolfgang Fleischhacker
    Department of Biological Psychiatry, Medical University Innsbruck, Innsbruck, Austria
    J Clin Psychiatry 69:514-9. 2008
    ....
  96. pmc Medical and substance-related comorbidity in bipolar disorder: translational research and treatment opportunities
    Roger S McIntyre
    Department of Psychiatry and Pharmacology, University of Toronto, ON, Canada
    Dialogues Clin Neurosci 10:203-13. 2008
    ..Subphenotyping bipolar disorder as a function of comorbidity and temporality of onset may provide an opportunity for refining disease pathophysiological models and developing innovative disease-modifying therapies...
  97. doi request reprint Adverse events in children and adolescents treated with antipsychotic medications
    Jeanette M Jerrell
    Department of Neuropsychiatry and Behavioral Science, University of South Carolina School of Medicine, South Carolina 29203, USA
    Hum Psychopharmacol 23:283-90. 2008
    ..To report the odds of developing adverse events associated with antipsychotic treatment among children and adolescents...
  98. pmc Bipolar depression: trial-based insights to guide patient care
    David E Kemp
    Case Western Reserve University, University Hospitals Case Medical Center, Cleveland, Ohio, USA
    Dialogues Clin Neurosci 10:181-92. 2008
    ..A pragmatic clinical approach is presented for management of the depressed phase of bipolar disorder...
  99. ncbi request reprint Assessing the prevalence of depression among individuals with diabetes in a Medicaid managed-care program
    Linda S Kahn
    State University of New York at Buffalo, USA
    Int J Psychiatry Med 38:13-29. 2008
    ....
  100. pmc Antipsychotic drugs and diabetes
    Roger S McIntyre
    CMAJ 168:673. 2003
  101. ncbi request reprint Obesity in bipolar disorder and major depressive disorder: results from a national community health survey on mental health and well-being
    Roger S McIntyre
    Department of Psychiatry and Pharmacology, University of Toronto, Ontario
    Can J Psychiatry 51:274-80. 2006
    ..We further aimed to examine the likelihood of an association between obesity and MD, while controlling for the influence of sociodemographic variables...